Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

New Drug Treatment Reduces Chronic Pain Following Shingles

Published: Friday, February 07, 2014
Last Updated: Friday, February 07, 2014
Bookmark and Share
New drug EMA401 reduce pain and did not cause any serious side effects.

A new drug treatment has been found to be effective against chronic pain caused by nerve damage, also known as neuropathic pain, in patients who have had shingles.

The researchers hope that the drug might also be effective against other causes of chronic neuropathic pain, such as diabetes, HIV, nerve injury and cancer chemotherapy, as it targets a mechanism that is not targeted by any existing therapies and has fewer side effects.

Drugs available now have limited success at treating neuropathic pain and often have unpleasant or disabling side effects.

It is estimated that around 190,000 people in the UK get shingles every year, most of them aged over 50. It is caused when a dormant viral infection of a nerve is reactivated, resulting in a painful rash. In most cases, the shingles rash lasts a few weeks, but in some cases the permanent nerve damage caused by the virus results in a chronic neuropathic pain called post-herpetic neuralgia. Around one in 10 people with shingles experiences post-herpetic neuralgia and, once established, it usually causes life-long suffering.

In a study involving 183 patients with post-herpetic neuralgia in six countries, the new drug EMA401 was found to reduce pain and did not cause any serious side effects.

Lead author Professor Andrew Rice, from the Department of Surgery and Cancer at Imperial College London, said: "Conventional painkillers don't tend to help people with severe chronic neuropathic pain and most available treatments have modest efficacy and/or are limited by side effects. We are therefore keen to find new ways of providing these people with some relief.

"A positive trial like this in such a challenging condition as post-herpetic neuralgia, for a drug that acts in a new way, is unusual and very exciting. We hope that the new drug will ultimately offer hope for patients who aren't helped by current treatments."

The study, a phase 2 trial, compared EMA401 with a placebo, with participants taking two pills a day for four weeks. Fifty-eight per cent of participants taking the drug found it effective, reducing pain by at least 30 per cent.

Spinifex Pharmaceuticals, which owns the drug, now plans to conduct a larger trial, possibly testing higher doses of the drug for longer periods of time.

"We are looking forward to seeing how EMA401 performs in a larger trial in people with post-herpetic neuralgia, where we will explore higher doses, and in trials where we will analyze its efficacy in other chronic pain conditions. Identifying the characteristics of the patients who do get good pain relief from EMA401 will also be an important avenue for research," added Professor Rice.

Tom McCarthy, CEO of Spinifex Pharmaceuticals, said: "There is a clear need for new treatments that bring patients pain relief with fewer side effects. In addition to post-herpetic neuralgia, we see broad potential for EMA401 to treat a range of chronic painful conditions such as pain due to osteoarthritis and diabetes. We look forward to delivering on the further development of EMA401."

Spinifex's clinical program for EMA401 includes a clinical trial in the treatment of neuropathic pain in patients after cancer chemotherapy, which is being conducted by Professor Praveen Anand at Imperial College London. Professor Anand's group also conducted key clinical tissue research which led up to the trials.

Professor Rice works with patients with neuropathic pain at Chelsea and Westminster Hospital, where he is a Consultant in Pain Medicine. He has worked with Spinifex through Imperial Consultants on the pre-clinical development of the new drug since 2005.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Technique Negotiates Neuron Jungle To Target Source Of Parkinson’s Disease
Researchers from Imperial College London and Newcastle University believe they have found a potential new way to target cells of the brain affected by Parkinson’s disease.
Wednesday, September 23, 2015
Designer Molecule Shines a Spotlight on Mysterious Four-Stranded DNA
A small fluorescent molecule has shed new light on knots of DNA thought to play a role in regulating how genes are switched on and off.
Thursday, September 10, 2015
Highly Effective Seasickness Treatment on the Horizon
The misery of motion sickness could be ended within five to ten years thanks to a new treatment being developed by scientists.
Monday, September 07, 2015
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Friday, September 04, 2015
Discovery of Trigger for Bugs’ Defences Could Lead to New Antibiotics
New research shows that sigma54 holds a bacterium’s defences back until it encounters stress.
Friday, August 21, 2015
Breakthrough Could Lead to New Antibiotics
Scientists have exposed a chink in the armour of disease-causing bugs, with a new discovery about a protein that controls bacterial defences.
Friday, August 21, 2015
New Drug Target Identified for Serious Heart and Lung Condition
A gene has been identified that sheds new light on a potentially fatal heart and lung condition and could lead to a new treatment.
Friday, August 14, 2015
Study Finds Brain Chemicals that Keep Wakefulness in Check
Researchers to develop new drugs that promote better sleep, or control hyperactivity in people with mania.
Saturday, August 01, 2015
Fossil Fuel Emissions will Complicate Radiocarbon Dating, Warns Scientist
The paper is published in the journal PNAS.
Tuesday, July 21, 2015
Scientists Find New Variant of Streptococcal Bacteria Causing Severe Infections
Researchers noticed a sharp rise in infections caused by emm89.
Wednesday, July 15, 2015
Gene Therapy for Cystic Fibrosis Shows Encouraging Trial Results
A therapy that replaces the faulty gene responsible for cystic fibrosis in patients' lungs has produced encouraging results in a major UK trial.
Friday, July 03, 2015
New Genetic Form of Obesity and Diabetes Discovered
Scientists have discovered a new inherited form of obesity and type 2 diabetes in humans.
Tuesday, June 30, 2015
New Genetic Form of Obesity and Diabetes Discovered
Scientists have discovered a new inherited form of obesity and type 2 diabetes in humans.
Tuesday, June 30, 2015
Researchers Develop New Breath Test to Diagnose Oesophageal and Gastric Cancer
Test will now be tested in a larger trial involving three hospitals in London.
Tuesday, June 23, 2015
'Crumpled' Filter to Slash Energy Consumption
Scientists have developed an ultra-thin, super-strong membrane to filter liquids and gases, with the potential to cut energy consumption in industry.
Friday, June 19, 2015
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos